thymic stromal lymphopoietin receptor chimeric antigen receptor T-cell therapy

Thymic stromal lymphopoietin receptor (TSLPR) chimeric antigen receptor (CAR) T-cell therapy is an autologous cellular immunotherapy designed to target TSLPR (encoded by the CRLF2 gene), which is overexpressed in a subset of high-risk B-cell acute lymphoblastic leukemias (B-ALL), particularly Philadelphia chromosome-like (Ph-like) ALL and Down syndrome-associated ALL (DS-ALL). The therapy involves genetically engineering a patient's own T cells to express a CAR targeting TSLPR, typically utilizing a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. Upon infusion, these modified T cells selectively bind to and eliminate TSLPR-expressing leukemia cells. Preclinical and clinical development of this therapy is primarily led by the National Cancer Institute (NCI) and the Children's Hospital of Philadelphia (CHOP).

Other names

anti-CRLF2-R/TSLPR CAR-T cell therapyanti-TSLPR CAR-T cell therapyTSLPR CAR-T cell therapyTSLPR-CARTTSLPR-redirected chimeric antigen receptor T-cell therapyTSLPRCART